Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q2 FY26 results · Jul–Sep 2025
Sun Pharma Advanced Research Company reported revenue from operations of ₹7.86 crore (down 38.9% from Q2 FY25) and net loss of ₹75.85 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 7.86 | 12.86 | −38.9% | 9.64 | −18.5% |
| Other income | 0.01 | 0.04 | −75.0% | 9.14 | −99.9% |
| Total income | 7.87 | 12.90 | −39.0% | 18.78 | −58.1% |
| Profit before tax | (75.79) | (107.17) | Loss narrowed | (51.81) | Loss widened |
| Net profit for the period | (75.85) | (107.33) | Loss narrowed | (51.87) | Loss widened |
| EPS, basic (₹) | (2.34) | (3.31) | Loss narrowed | (1.60) | Loss widened |
| Net margin (%) | -965.0 | -834.6 | -538.1 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 7.86 | 12.86 | −38.9% | 9.64 | −18.5% |
| Other income | 0.01 | 0.04 | −75.0% | 9.02 | −99.9% |
| Total income | 7.87 | 12.90 | −39.0% | 18.66 | −57.8% |
| Profit before tax | (75.97) | (107.69) | Loss narrowed | (52.03) | Loss widened |
| Net profit for the period | (75.97) | (107.69) | Loss narrowed | (52.03) | Loss widened |
| EPS, basic (₹) | (2.34) | (3.32) | Loss narrowed | (1.60) | Loss widened |
| Net margin (%) | -966.5 | -837.4 | -539.7 |
Consolidated
- Filed with BSE
- 10 Nov 2025, 22:09 IST
- Board meeting
- 10 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Nov 2025, 22:09 IST
- Board meeting
- 10 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE